Coya Therapeutics (NASDAQ:COYA) Releases Earnings Results, Beats Estimates By $0.07 EPS

Coya Therapeutics (NASDAQ:COYA) posted its quarterly earnings data on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07, Zacks reports. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 53.20%.

Coya Therapeutics Price Performance

Shares of COYA stock opened at $4.69 on Thursday. The stock has a market cap of $110.01 million, a PE ratio of -4.38 and a beta of 0.60. The stock has a 50-day moving average of $4.86 and a 200-day moving average of $4.67. Coya Therapeutics has a one year low of $3.71 and a one year high of $7.75.

Hedge Funds Weigh In On Coya Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Prosperity Wealth Management Inc. boosted its position in Coya Therapeutics by 16.4% during the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after acquiring an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. bought a new stake in shares of Coya Therapeutics in the third quarter worth $28,000. CIBC Private Wealth Group LLC bought a new stake in shares of Coya Therapeutics in the fourth quarter worth $47,000. Occudo Quantitative Strategies LP bought a new position in Coya Therapeutics in the fourth quarter valued at $66,000. Finally, Dimensional Fund Advisors LP grew its position in Coya Therapeutics by 58.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 31,429 shares of the company’s stock valued at $182,000 after purchasing an additional 11,648 shares in the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on COYA. Wall Street Zen downgraded Coya Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Chardan Capital restated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday. Roth Capital initiated coverage on shares of Coya Therapeutics in a report on Friday, June 5th. They set a “buy” rating and a $12.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Coya Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.